CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Industries to Neutral from Buy after the building materials company reported weaker quarterly earnings and lowered its guidance on North America, its largest market.